==== Front Gut Pathog Gut Pathog Gut Pathogens 1757-4749 BioMed Central London 37386612 552 10.1186/s13099-023-00552-1 Case Report Clostridioides difficile infection in infants: a case report and literature review Li Zhirong 1 Dong Ning 1 Hao Jihong 2 Ouyang Zirou 1 Qiang Cuixin 1 Yang Ying 1 Mi Chaoyi 3 Niu Yanan 1 Yang Jing 1 Wen Baojiang 1 Wang Liwei 5 Zhang Shaodan 13653115066@163.com 46 Zhao Jianhong zhaojh_2002@hebmu.edu.cn 126 1 grid.452702.6 0000 0004 1804 3009 Hebei Provincial Center for Clinical Laboratories, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei China 2 grid.452702.6 0000 0004 1804 3009 Department of Clinical Laboratory, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei China 3 grid.452582.c Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011 Hebei China 4 grid.452702.6 0000 0004 1804 3009 Department of Pediatrics, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei China 5 Clinical Laboratory, Shexian Hospital, Handan, 050000 Hebei China 6 215# Hepingxi road, Shijiazhuang, Hebei province China 29 6 2023 29 6 2023 2023 15 3113 2 2023 11 5 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Background Clostridioides difficile (C. difficile) is the major pathogen causing antibiotic-associated diarrhea. There are a variety of symptoms associated with C. difficile infection (CDI) in adults, including self-limiting diarrhea, pseudomembranous colitis, toxic megacolon, septic shock, and even death from the infection. However, the infant’s intestine appears to be completely resistant to the effects of C. difficile toxins A and B with rare development of clinical symptoms. Case presentation In this study, we reported a 1-month-old girl with CDI who was born with neonatal hypoglycemia and necrotizing enterocolitis. Her symptom of diarrhea occurred after extensive use of broad-spectrum antibiotics during hospitalization and was accompanied by elevated white blood cell, platelet, and C-reactive protein levels, and repeated routine stool examinations were abnormal. She was recovered by norvancomycin (an analogue of vancomycin) and probiotic treatment. The results of 16 S rRNA gene sequencing also demonstrated the recovery of intestinal microbiota with the enrichment of Firmicutes and Lactobacillus. Conclusions Based on the literature review and this case report, clinicians should also pay attention to diarrhea caused by C. difficile in infants and young children. More strong evidence is needed to explain the true prevalence of CDI in this population and to better understand the C. difficile-associated diarrhea in infants. Supplementary Information The online version contains supplementary material available at 10.1186/s13099-023-00552-1. Keywords Clostridioides difficile CDI Antibiotic-associated diarrhea Intestinal microbiota Infant Hebei Natural Science FoundationH2022206549 H2022206358 Special Foundation for National Science and Technology Basic Research Program of ChinaN2019FY101200, 2019FY101204 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2023 ==== Body pmcIntroduction Clostridioides difficile (C. difficile) is a Gram-positive anaerobic bacillus that is a major pathogen causing healthcare-associated infections [1]. Since the early 21st century, Clostridioides difficile infection (CDI) has been a major global public health problem, and is considered an “urgent threat” to human health by the United States Centers for Disease Control and Prevention [2]. C. difficile pathogenicity is mediated by the protein toxins A and B (encoded by tcdA and tcdB, respectively), which cause clinical symptoms ranging from self-limited diarrhea to life-threatening pseudomembrous colitis, toxic megacolon, and even death [3, 4]. The burden of this disease has increased over the past few decades, especially outbreaks of the hypervirulent strain RT027/NAP1/BI, increasing the morbidity and mortality of hospital-acquired infections worldwide [5]. It is estimated that CDI is responsible for over 500,000 enteric infections, 29,000 deaths and over $4.8 billion in healthcare costs each year in the United States [6]. In addition, CDI is no longer restricted to the hospital setting, and higher rates have been reported in traditionally low-risk populations, including children who have not been exposed to hospital settings [7]. A CDI treatment plan depends on whether it is an initial or recurrent episode, as well as its severity [8]. The first episode of non-severe or severe CDI can be treated with vancomycin or fidaxomicin. For fulminant CDI, vancomycin is the treatment of choice. In the event of ileus, vancomycin may also be administered through the rectum. Especially if an ileus is present, it is recommended to administer oral or rectal vancomycin with intravenous metronidazole. The first recurrence of CDI can be treated with oral vancomycin or fidaxomicin for 10 days, or a prolonged taper of pulse oral vancomycin. CDI patients with a second or subsequent recurrence can be treated with oral vancomycin therapy using a tapered and pulsed regimen, fidaxomicin, and vancomycin followed by Rifaximin or fecal microbiota transplantation (FMT). It is thought that CDI develops because of an imbalance in the host intestinal microbiota, which can be caused by a variety of factors. Broad-spectrum antimicrobials are considered to be the most important risk factor for CDI in adults and children by destroying the host intestinal microbiota and reducing colonization resistance to C. difficile and other enteric pathogens [9]. Earlier studies have shown a marked reduction in bacterial diversity among subjects with CDI. CDI patients were enriched with Enterococcus, Enterobacteriaceae, Erysipelotrichaceae, and Gammaproteobacteria class, but there was a decrease in Ruminococcaceae, Lachnospiraceae, Bacteroidetes, and Clostridial clusters IV and XIVa [10]. The epidemiology of C. difficile in children is characterized by asymptomatic colonization in many infants, with the highest colonization rates (which can exceed 40%) particularly among infants younger than 12 months of age [11]. Thus, the consensus guidelines recommend testing for C. difficile only if infants (< 12 months of age) present with pseudomembranous colitis or toxic megacolon or if they have symptoms of clinically significant diarrhea in which other causes of diarrhea have been ruled out [8]. However, a study based on children with diarrhea in Kenya showed that children with diarrhea were more susceptible to C. difficile infection than children with rotavirus or Cryptosporidium infection [12]. Here, we describe the clinical manifestations, diagnosis, treatment, changes in the intestinal microbiota of a pediatric patient with CDI, and reviewed the literature to improve clinicians’ awareness of CDI. Case presentation Clinical presentation The pediatric patient was a 1-month-old female who came to the outpatient department for the first time due to diarrhea (7–8 loose yellow stools/day) more than 20 days ago. Diarrhea continued after treatment with cefixime and probiotics (Saccharomyces boulardii). She was admitted to our hospital on March 4, 2021. The infant was born by caesarean section at full term and was diagnosed with hypoglycemia and necrotizing enterocolitis (NEC). She was treated with broad-spectrum antibiotics during hospitalization, including cefoperazone, meropenem, piperacillin, tazobactam, sulbactam, fluconazole, vancomycin, and azithromycin. Clinical findings Clinical examination on admission revealed: temperature, 36.8℃; heart rate, 136 beats/min; and respiratory rate, 35 breaths/min. The infant was conscious and presented pharyngeal hyperemia, mildly swollen tonsils, and coarse breath sounds. The patient did not have fine wet rales and lower limb edema. Diagnostic focus and assessment Laboratory tests performed on the day of admission revealed the following results: white blood cell count, 26.3 × 109/L; neutrophil count, 11.47 × 109/L; lymphocyte count, 6.87 × 109/L; red blood cell count, 3.36 × 1012/L; hemoglobin, 104 g/L; platelet count, 599 × 109/L; C-reactive protein (CRP), 157.2 mg/L; albumin, 31.4 g/L; lactate dehydrogenase, 355.0 U/L; and procalcitonin, 0.20 ng/ml. Stool routine examination showed a fecal white blood cell count of 99 − 120 per high power field (HPF) and fecal red blood cell count of 15 − 25/HPF (Supplementary Table S1). Bone marrow aspiration revealed granulocytosis and thrombocytosis and a granulocytic-to-erythroid ratio of 23%. Stool cultures revealed Enterococci as the main bacteria, with intestinal parasites, rotavirus, and common bacterial intestinal pathogens (Shigella, Salmonella, Pathogenic Escherichia coli, etc.) remaining undetected. After admission, she was initially diagnosed with neonatal acute diarrhea according to the Textbook of Pediatrics (9th edition, People’s Health Publishing House, 2018) [13]. In this case, a laboratory test revealed elevated white blood cell count and CRP in peripheral blood, bloody purulent stool, and a routine stool examination revealed increased white and red blood cells. After excluding the above intestinal pathogens, the pathogen of this case was considered to be invasive bacteria, and empirical treatment was performed with cefmenoxime and norvancomycin (an analogue of vancomycin). After 3 days of treatment, the frequency of diarrhea decreased to about 4 times/day. Given the patient’s long-term history of antibiotic use, C. difficile related tests were performed on the 3rd and 7th day of admission. As a result, enzyme immunoassay (EIA) for C. difficile glutamate dehydrogenase (GDH) and nucleic acid amplification tests (NAATs) for toxin genes were positive. Bacterial culture revealed colonies of C. difficile, which were confirmed to be sequence typing 54 by multilocus sequence typing. Based on the above test results, the patient was finally diagnosed with CDI, so cefmenoxime was discontinued and norvancomycin was continued. Therapeutic focus and assessment After we treated the patient with norvancomycin for 12 days, the infant stool frequency decreased, about 2–3 times/day, and the stool was sticky, with no fever, nausea, or abdominal pain, and was discharged. After discharge, intravenous antibiotics were discontinued and changed to a combination of oral norvancomycin and probiotics. The patient was treated with three courses of antibiotics with oral norvancomycin after hospital discharge. After the first course (9 days) of treatment, the infant’s stools were viscous (Fig. 1a) with a frequency of about 3 times/day, and routine stool examination shows normal white and red blood cell counts (Supplementary Table S1). However, 7 days after treatment withdrawal, the patient began to have frequent loose stools (Fig. 1b), about 6 times/day. The routine stool examination showed elevated white blood cell count (Supplementary Table S1). C. difficile toxigenic culture (TC) and NAATs were positive. The second course of antibiotics was started based on symptoms and test results. After 25 days of treatment, the patient’s routine stool examination and frequency returned to normal (2–3 times/day) (Supplementary Table S1). The stool was mushy (Fig. 1c), and stool culture and NAATs were negative. Ten days after treatment discontinuation, the patient began to have frequent loose, mucus-containing stool (Fig. 1d), approximately 5 times/day. The routine stool examination showed fecal white blood cell count of 26–44/HPF (Supplementary Table S1), TC and NAATs were positive. The treatment period was extended based on clinical symptoms and the recurrence of diarrhea. In the third course, the dose of norvancomycin was adjusted five times sequentially according to clinical status as follows: 0.06 g twice a day for 10 days, 0.06 g four times a day for 29 days, 0.06 g twice a day for 17 days, 0.07 g once a day for 11 days, and 0.07 g once every 2 days for 31 days. Stool frequency returned to normal after the third course of treatment, about 2 times/day, the stool was normal (Supplementary Table S1), stool culture of C. difficile, GDH/toxin EIA, and NAAT were negative (Fig. 1e and f). The diagnosis and treatment details are shown in Fig. 2. Fig. 1 Stool characteristics during treatment. a Viscous stool after the first course of treatment; b Loose and yellow stool after treatment withdrawal; c Mushy stool after the second course of treatment; d Loose and yellow stool after treatment withdrawal; e Normal stool after the third course of treatment; f Normal stool during the 3-month follow-up Fig. 2 Diagnosis and treatment of Clostridioides difficile infection. Samples were numbered according to the date of collection. The treatment cycle was divided into six stages (S1 to S6) according to sampling time and treatment dose. S1 to S5 correspond to different treatment doses, and S6 is the recovery stage 16 S rRNA gene-based fecal microbiota profiling To assess changes in the fecal microbiota during treatment, the treatment course was divided into six stages (S1 to S6) (≥ 3 stool samples per stage) according to sampling time and treatment dose (Figs. 2 and 3). S1 to S5 corresponded to different treatment doses, and S6 was the recovery stage. Samples were collected in a sterile collection tube, and stored at -80℃ until analysis. Fig. 3 Composition, abundance, diversity, and predominance of intestinal microorganisms in our patient. a Phylum-level taxonomic distribution of the microbial community; b Family-level taxonomic distribution of the microbial community; c Genue-level taxonomic distribution of the microbial community; d-e Alpha diversity analysis (Chao and Shannon index) of metagenomic sequencing data (≥ 3 samples per stage). Data are mean ± SEM. Differences between data were assessed using the Kruskal-Wallis test and Dunn’s test. *P < 0.05; f Principal coordinate analysis of metagenomic sequencing data at different stages (≥ 3 samples per stage); g-i Relative abundance of bacterial phyla (g), families (h) and genus (i) at different stages; j-k Predominant microorganisms across stages (≥ 3 samples per stage). (j) Hierarchical tree diagram based on linear discriminant analysis effect size; (k) Distribution histogram based on linear discriminant analysis The OMEGA Soil DNA Kit (M5635-02) (OMEGA Bio-Tek, Norcross, GA, USA) was used to extract total genomic DNA from stool samples. The fecal microbiota characteristics were determined by sequencing the V3-V4 region of the 16 S rRNA gene using the Illlumina NovaSeq platform with NovaSeq 6000 SP Reagent Kit (500 cycles) at Shanghai Personal Biotechnology Co., Ltd (Shanghai, China). QIIME2 2019.4 was used for microbiome bioinformatics with slight modifications in accordance with the official tutorials (https://docs.qiime2.org/2019.4/tutorials/). Sequence data were demultiplexed using the demux plugin, followed by primers being cut with the cutadapt plugin. The DADA2 plugin then filtered, denoised, merged, and removed chimera from sequences [14]. An amplicon sequence variant (ASV)’s taxonomy was assigned using the classify-sklearn Naive Bayes classifier (Greengenes Database) in the feature-classifier plugin [15]. In order to obtain the sharing information between groups, the relative abundance of ASVs and Venn diagram was analyzed. Each group’s Alpha diversity level was then calculated based on the distribution of ASVs. In addition, to measure the difference in beta diversity between each group, the distance matrix for each sample was calculated, and the principal coordinate analysis (PCoA) was performed. Composition analysis of the fecal microbiota of each sample is shown in Fig. 3a and c. Alpha diversity (Chao and Shannon indexes) was significantly higher at S6 than at S1, S2, S3, and S4 (P < 0.05, Fig. 3d and e). PCoA based on the Bray-Curtis distance showed a separation in the fecal microbiota structure at S5 and S6 relative to S2 (P < 0.005, Fig. 3f), indicating that the microbiota was significantly impacted by treatment. At the phylum level, Firmicutes was enriched at S5 and S6 (Fig. 3g). At the family level, Veillonellaceae and Lactobacillaceae were enriched (Fig. 3h). At the genus level, Veillonella and Lactobacillus were enriched (Fig. 3i). Bacterial phylotypes were identified at each stage using linear discriminant analysis effect size. The results showed no significant differences in phylotypes across stages (Fig. 3j and k). Fecal microbiota composition reflected by alpha and beta diversity changed over time, possibly due to CDI. Follow-up and outcomes Following three courses of norvancomycin treatment, stool frequency returned to normal, and diarrhea did not recur during three months of follow-up. Discussion and conclusions Early childhood is a crucial period during which the intestinal microbiota may impact current and future health status [16]. In adults, C. difficile primarily colonizes the lower intestinal tract and causes colonic inflammation by binding to toxins A and B to receptors on the plasma membrane [17, 18]. However, children’s intestines appear to be resistant to the effects of these toxins, and clinical infections are rare. C. difficile has been recovered from an average of 37% of stools in healthy infants younger than 1 month. The colonization rate decreases to approximately 30% between 1 and 6 months of age. During the first year of life, this rate declines until it reaches 10% in healthy infants. At 3 years old, the colonization rate is approximately 3%, similar to the adult carrier rate [19–21]. Neonatal resistance to CDI may be related to the absence of toxin receptors, downstream signaling pathways in the immature intestinal mucosa, and some protective factors in breast milk and the host intestinal microbiota [22, 23]. Therefore, the consensus guidelines recommend clinical testing for CDI only in the presence of clinical indications [8]. In recent studies, 26% of children hospitalized with CDI were younger than 1 year of age, and 5% were newborns [24]. Pediatric CDI is caused by a variety of factors, including age, gender, comorbidities, prolonged hospitalization and enteral feeding, but antibiotic exposure appears to be the main risk factor [25]. In spite of the fact that nearly all antibiotic classes can cause CDI, clindamycin, cephalosporins, and fluoroquinolones appear to pose the greatest threat [26]. Broad-spectrum antibiotic treatment can damage the host intestinal microbiota and reduce intestinal commensal flora diversity and beneficial bacteria abundance, leading to excessive growth and toxin production of C. difficile [27, 28]. Following the discontinuation of antibiotic treatment, these effects can persist for weeks or months, predisposing individuals to C. difficile infections.[29]. There is a wide range of clinical manifestations of CDI. It is possible for patients with a mild infection to have a single episode of diarrhea, as well as abdominal pain, bloody stools, purulent stools, or watery stools. In severe cases, patients may develop pseudomembranous colitis, fulminant colitis, toxic megacolon, and sepsis [4]. In this study, we searched Wanfang Data, China National Knowledge Infrastructure, and the Biomedical Literature Database (PubMed) for case reports on CDI in children. Studies that did not exclude other pathogens and had unclear detection methods related to C. difficile were excluded. A summary of the national and international studies is listed in Table 1 [30–40]. Combined with the literature review, the main clinical manifestations of CDI in children are fever, diarrhea, abdominal pain, vomiting and pseudomembranous colitis, and some children have rare clinical manifestations such as reactive arthritis. Increased white blood cell and CRP counts were found in laboratory tests. Our patient was treated with broad-spectrum antibiotics during hospitalization for hypoglycemia and NEC at birth. In the early stage of the onset, the main manifestations were diarrhea (loose yellow stool), repeated routine stool examinations were abnormal, and toxigenic C. difficile, GDH, and NAATs were positive. After excluding other causes, the patient was finally diagnosed with CDI. Table 1 Cases of Clostridioides difficile infection in children Author Year Age Sex Exposure Symptoms Laboratory results Other pathogens Comorbidities Detection of C. difficile Treatment Outcome Cappella M et al.[30] 2016 6-year Male Amoxicillin-clavulanate Watery diarrhea, abdominal pains, fever, reactive Arthritis CRP, mg/L: 39 Erythrocyte sedimentation rate, mm/h: 30 Salmonella (-); Shigella (-); Yersinia (-); Campylobacter (-); Viruses (-) No ELISA (Toxins) Oral naproxen and metronidazole Cured Durand CL et al.[31] 2009 10-year Female Erythromycin; Penicillin Hip pain, diarrhea, fever, reactive Arthritis CRP, mg/dL: 12 WBC, 109/L: 15.4 Bacteria (-); Viruses (-); Ova (-); Cysts (-); Parasites (-) No ELISA (Toxins) Oral and intravenous metronidazole Cured Liang Y et al.[32] 2020 6-year Female Chemotherapy; Cephalosporin; Vancomycin; Imipenem; Carprofen Fever, diarrhea with jelly-like stools, abdominal distension, nausea, vomiting, shortness of breath, massive hydrothorax and ascites CRP, mg/L: 220 WBC, 109/L: 15.4 Hemoglobin, g/dL: 6.9 Albumin, g/dL: 2.8 Dehydrogenase, U/L: 282 Common bacteria and fungiculture (-); Rotavirus (-); Adenoviridae antigens (-) Lymphoma RT-PCR (Toxin gene) Oral vancomycin and Saccharomyces boulardii Cured Rojas GM et al.[33] 2018 5-month Female No Watery diarrhea, abdominal distension WBC, 103/µL: 9.5 CRP, mg/dL: 18 Erythrocyte sedimentation rate, mm/h: 64 Salmonella (-); Shigella (-); E. coli O157:H7 (-); Vibrio (-); Yersinia (-); Campylobacter (-) Kawasaki disease PCR (Toxin gene) Oral metronidazole NA Rojas GM et al.[33] 2018 4-year Male Penicillin Non-bilious, non-bloody vomiting and abdominal distension WBC, 103/µL: 9.2 CRP, mg/dL: 17.6 Erythrocyte sedimentation rate, mm/h: 110 Salmonella (-); Shigella (-); E. coli O157:H7 (-); Vibrio (-); Yersinia (-); Campylobacter (-) Kawasaki disease PCR (Toxin gene) Oral metronidazole NA Price EH et al.[34] 1988 2-month Female No Non-bloody diarrhea, vomiting, fever, acute enterocolitis WBC, 109/L: 4.4 PLT, 109/L: 305–616 Campylobacter (-); enteropathogenic Escherichia coli (-); Salmonella (-); Shigella (-); Viruses (-); E coli 013 (a non-enteropathogenic serotype) (+); Yersinia enterocolitica (-); Pseudotuberculosis (-) No TC Intravenous metronidazole Cured Price EH et al.[34] 1988 3-week Female Anticholinergic drug (pipenzolate bromide) Profuse watery, but non-bloody diarrhea, acute enterocolitis WBC, 109/L: 20.5 PLT, 109/L: 25,000 enteropathogenic E coli (-); Salmonella (-); Shigella (-); Campylobacter (-); Viruses (-); Yersinia enterocolitica (-) No TC Intravenous benzylpenicillin, gentamicin and metronidazole Cured Loffler HA et al.[35] 2004 6-year Female NA Fever, nausea, vomit, watery diarrhea, reactive arthritis WBC, 109/L: 16.9 CRP, mg/L: 21 Erythrocyte sedimentation rate: 61 mm/h Fibrinogen, g/L: 9 Yersinia enterocolitica (-); Shigella (-); Salmonella (-); Campylobacter (-) No EIA (Toxins) Diclofenac and vancomycin Cured Nogueira H et al.[36] 2021 2.5-year Female Immunosuppressive medication (Prednisone/Tacrolimus/Mycophenolate sodium) Bloody and mucoid stool WBC, /mm3: 10,420 Hemoglobin, g/dL: 10.5 Intestinal parasites (i.e. protozoa and helminths) (-); Gastrointestinal viruses (-); Enteric pathogens (-) Liver transplantation TC; EIA (Toxins) Metronidazole Cured Quesada-Gomez C et al.[37] 2012 18-month Female Azithromycin; Diclofenac Watery diarrhea with mucous Normal Protozoa (-); Helminthes (-); Gastrointestinal viruses (-); Bacterial enteric pathogens (-) No TC, EIA (Toxins) Metronidazole and probiotic (commercial Saccharomyces and Bacillus spores) Cured Yang Hongbin et al.[38] 2018 2-year Female Cephalosporin Diarrhea WBC, 109/L: 14.63 PLT, 109/L: 539 Mycobacterium tuberculosis (-); Cytomegalovirus (-); Herpes simplex virus (-) No Colonoscopy; EIA (GDH/Toxins) Oral metronidazole and probiotics (Bacillus subtilis) Cured Guan Jun et al.[39] 2017 6-year Female Cefadroxil; Cephalosporins; Cefixime Diarrhea, abdominal pain ALT:9.0 IU/L AST: 30I U/L Alpha hydroxybutyrate dehydrogenase, IU/L: 455 Lactic dehydrogenase, IU/L: 509 Shigella (-); Salmonella (-); Pathogenic Escherichia coli (-); Vibrio cholerae (-); Campylobacter jejuni (-); Rotavirus (-); Enterovirus (-); Cytomegalovirus (-); EB virus (-) No Colonoscopy; EIA (GDH/Toxins) Oral metronidazole and probiotics (Saccharomyces boulardii) Cured Kader A et al.[40] 2004 7-week Male No Loose stools and faltering weight WBC, 109/L: 21.05 CRP, mg/L: 45 Bacteria (-); Viruses (-); Ova (-); Cysts (-) No ELISA (Toxins) Oral metronidazole Cured Our patient 2021 1-month Female Piperacillin, tazobactam, cefoperazone, sulbactam, fluconazole, vancomycin meropenem and azithromycin Diarrhea, loose yellow stools WBC, 109/L: 26.30 PLT, 109/L: 599 HsCRP, mg/L: 157.2 Protozoa and helminths (-); Rotavirus (-); Shigella (-); Salmonella (-); Pathogenic Escherichia coli (-); Plesiomonas and Aeromonas (-) No TC, NAAT, Combined GDH and toxin EIA Intravenous norvancomycin and oral norvancomycin, probiotics Cured Clinical history and laboratory tests are essential for the accurate diagnosis of CDI. This patient had diarrhea symptoms, abnormal stool routine examinations, and increased white blood cell count, CRP and muscle enzymes, which may be related to acute enteritis at the early stage of the disease. This clinical manifestation is difficult to distinguish from intestinal diseases caused by other predisposing factors. Therefore, the diagnosis of CDI in children remains an incredible clinical challenge. CDI is defined by the presence of symptoms (usually diarrhea) and either a stool test positive for C. difficile toxins or detection of toxigenic C. difficile or colonoscopic or histopathologic findings revealing pseudomembranous colitis [8]. However, no single laboratory test is considered the best. An immunoassay for GDH detects a highly conserved metabolic enzyme (common antigen) present in all isolates of C. difficile. GDH immunoassays cannot distinguish toxigenic C. difficile strains and lack specificity, so it is often used as a primary screening test for CDI [8]. TC has a high sensitivity (94–100%) and specificity (99%) which makes it a gold standard for laboratory diagnosis, but it has high experimental requirements and is not suitable for widespread use in clinical laboratories [41]. In addition, NAATs are capable of detecting the genes encoding C. difficile toxins A and B, making them an effective way to detect C. difficile [42]. However, when used in populations with high rates of C. difficile colonization, they may cause overdiagnosis of CDI due to their sensitivity [43]. Toxins in stool can distinguish colonization from infection more precisely, although recent studies have shown that asymptomatic children are more likely to have positive toxins in stool [44, 45]. The toxin EIA for C. difficile toxins A and/or B is inexpensive and easy to perform, but it is less sensitive than NAATs for detecting CDI and should not be used as a standalone test [8]. Consequently, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) have provided some valuable recommendations for the laboratory diagnosis of C. difficile in adults and children [8]. To begin with, C. difficile testing should only be performed in patients with three or more unexplained unformed stools within 24 h. As a second recommendation, routine testing should be avoided in children under the age of 12 months unless other possible causes have been ruled out. Furthermore, ESCMID recommends multiple-step test for the accurate diagnosis of CDI [46]. The first test should be GDH assay or NAAT, which has a high negative predictive value. If the result is positive, the second assay should be highly specific, such as toxin EIA, which has a high positive predictive value. If the second test is positive, the final diagnosis is CDI. Patients with a negative second test for toxins should be re-evaluated (TC or NAATs) for the possibility of true infection. In this study, after excluding other potential causes, the infant was first tested for GDH combined with toxins by EIA, and the results showed GDH (+) and Toxins (-). Subsequently, to further evaluate whether the infant was truly infected, we performed TC and NAATs, and the results were positive. Finally, combined with the clinical symptoms, the patient was diagnosed with CDI. Antibiotic therapy remains the first line of treatment of CDI, and antibiotics should be chosen according to guidelines and severity of the infection [41]. Currently, the treatment of CDI in children is based on clinical data from adults [47]. For children with their first episode or first recurrence of non-severe CDI, metronidazole and vancomycin are recommended. Oral vancomycin is preferred over metronidazole for children with a first episode of severe CDI [8]. Notably, new antibiotics may further disrupt intestinal microbiota, with approximately 25% of patients experiencing relapses within 4 weeks after antibiotic treatment [48]. FMT helps re-establish the intestinal microbiota and has a higher success rate than vancomycin when treating CDI that has relapsed/refractory [49]. Moreover, several studies have shown that probiotics reduce the incidence of antibiotic-associated diarrhea, and Saccharomyces boulardii, Lactobacillus acidophilus, Lactobacillus casei, and Lactobacillus rhamnosus can prevent primary or recurrent CDI [50–52]. In this case, after 3 days of intravenous norvancomycin (North China Pharmaceutical Company, China) according to the instructions, the frequency of diarrhea decreased. After continuing treatment with norvancomycin for 9 days, the infant’s stool frequency was normal, about 3 times/day, mainly viscous stools, and the condition was significantly improved. Stool culture of C. difficile and NAATs were still positive. After discharge, the patient was given oral norvancomycin and probiotic consolidation therapy. However, during this period, the patient had two relapses of diarrhea, accompanied by abnormal stool routine examination, C. difficile toxigenic culture, and NAATs were positive. Based on the clinical manifestations and laboratory diagnosis of the patient, the duration of the final treatment stage was extended, and the dose was adjusted in time according to the clinical status. Finally, her stool frequency returned to normal after three rounds of oral norvancomycin treatment. The patient had no recurrence of diarrhea, stool culture of C. difficile, GDH EIA, toxin EIA, and NAATs were negative during the 3-month follow-up period. The ecology of the intestinal microbiota determines C. difficile colonization and virulence [53]. It has been reported that the alpha diversity of the intestinal microbiota decreased significantly in infants with NEC, and the abundance of Bifidobacterium and Lactobacillus decreased [54, 55]. The strictly anaerobes in the intestinal of patients with NEC are Clostridium species (C. butyricum, C. neonatale, C. perfringens, C. paraputrificum, and C. difficile), which are associated with NEC in preterm infants [56, 57]. Therefore, in our case, we hypothesized that the intestinal microbiota was altered by NEC and antibiotic therapy, facilitating the development of CDI. However, the relationship between NEC and CDI still needs to be further elucidated. On the other hand, the microbiota differs between caesarean section born and vaginally delivered infants over the first year of life, showing enrichment of Enterococcus, Enterobacter, Clostridium perfringens and Klebsiella, and reduction of Bacteroides and Bifidobacterium in caesarean section born infants [58–61]. Our patient was born by caesarian section. These data suggested that caesarian section may also be a risk factor for CDI in infants. In the recovery of diseases, the intestinal microbiota plays an equally important role. Studies have shown that the abundance of Firmicutes and Bacteroidetes decreased while the abundance of Proteobacteria increased in children with toxin-positive C. difficile [62]. In the present study, the intestinal microbiota improved in the late stage of treatment and recovery period, demonstrated by the enrichment of Firmicutes and Lactobacillus and the increase in alpha diversity. Lactobacillus species, used as probiotics, regulate the intestinal microbiota, reduce intestinal inflammation, enhance host immune function, maintain the integrity of the intestinal barrier, and inhibit the production of toxins A and B [63, 64]. On the other hand, increased alpha diversity in the intestinal microbiota was also associated with age and complementary feeding [16, 65]. The effect of age and formula feeding in recovery was also considered during the study period. Further studies are necessary to determine the evolution and characteristics of the intestinal microbiota to better understand the relationship between C. difficile-associated dysbiosis and infant development. In summary, based on the literature review and this case report, clinicians should also pay attention to diarrhea caused by C. difficile in infants and young children. More strong evidence is needed to explain the true prevalence of CDI in this population and to better understand the C. difficile-associated diarrhea in infants. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1: Table S1. Results of laboratory tests during the clinical course Author contributions Jianhong Zhao, Zhirong Li, Ning Dong, Zirou Ouyang, Yang Ying and Chaoyi Mi took part in drafting, revising or critically reviewing the article; Jianhong Zhao, Shaodan Zhang, Jihong Hao, Cuixin Qiang, Yanan Niu, Jing Yang, Baojiang Wen, and Liwei Wang gave final approval of the version to be published; Jianhong Zhao, Zhirong Li, Ning Dong and Jihong Hao have agreed on the journal to which the article has been submitted, and agree to be accountable for all aspects of the work. All authors reviewed the manuscript. Funding This study was funded by the Special Foundation for National Science and Technology Basic Research Program of China (Grant No. 2019FY101200, 2019FY101204) and Hebei Natural Science Foundation (Grant No. H2022206549, H2022206358). Data availability All data generated or analyzed during this study are included in this published article and its supplementary information files. The metagenomic sequences of intestinal microbiota are available in the NCBI Sequence Read Archive (SRA) (https://www.ncbi.nlm.nih.gov/sra) under BioProject accession number PRJNA961946. Declarations Competing interests The authors declare no competing interests. Ethics approval and consent for participate The studies involving human participants were reviewed and approved by The Second Hospital of Hebei Medical University (Approval No. 2021-R521). The participants or legal guardians gave written informed consent to participate in this study. Consent for publication Written informed consent for publication of case details and any accompanying images was obtained from the patient’s parents described in this report. Abbreviations CDI Clostridioides difficile infection FMT Fecal microbiota transplantation NEC Necrotizing enterocolitis CRP C-reactive protein HPF High power field EIA Enzyme immunoassay NAATs Nucleic acid amplification tests TC Toxigenic culture ASVs Amplicon sequence variants PCoA Principal coordinate analysis GDH Glutamate dehydrogenase IDSA Infectious Diseases Society of America SHEA Society for Healthcare Epidemiology of America WBC White blood cells PLT Platelets PCR Polymerase chain reaction ELISA Enzyme-linked immunosorbent assay CCNA Cell culture cytotoxicity neutralization assay RT-PCR Real-time polymerase chain reaction NA Not available Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Zhirong Li, Ning Dong contributed equally to this work. ==== Refs References 1. Mileto S, Das A, Lyras D. Enterotoxic clostridia: Clostridioides difficile infections. MICROBIOL SPECTR. 2019;7. 2. Miller BA Chen LF Sexton DJ Anderson DJ Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant staphylococcus aureus in community hospitals INFECT CONT HOSP EP 2011 32 387 90 10.1086/659156 3. Janoir C Virulence factors of Clostridium difficile and their role during infection Anaerobe 2016 37 13 24 10.1016/j.anaerobe.2015.10.009 26596863 4. Fletcher JR Pike CM Parsons RJ Rivera AJ Foley MH McLaren MR Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota NAT COMMUN 2021 12 462 10.1038/s41467-020-20746-4 33469019 5. Peery AF Dellon ES Lund J Crockett SD McGowan CE Bulsiewicz WJ Burden of gastrointestinal disease in the united states: 2012 update Gastroenterology 2012 143 1179 1187e3 10.1053/j.gastro.2012.08.002 22885331 6. Heimann SM Cruz AM Mellinghof S Vehreschild M Economic burden and cost-effective management of Clostridium difficile infections MED MALADIES INFECT 2018 48 23 9 10.1016/j.medmal.2017.10.010 7. Honda H Dubberke ER The changing epidemiology of Clostridium difficile infection CURR OPIN GASTROEN 2014 30 54 62 10.1097/MOG.0000000000000018 8. McDonald LC Gerding DN Johnson S Bakken JS Carroll KC Coffin SE Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA) CLIN INFECT DIS 2018 66 e1 e48 10.1093/cid/cix1085 29462280 9. Furuya-Kanamori L Stone JC Clark J McKenzie SJ Yakob L Paterson DL Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis INFECT CONT HOSP EP 2015 36 132 41 10.1017/ice.2014.39 10. Theriot CM Young VB Interactions between the gastrointestinal microbiome and Clostridium difficile ANNU REV MICROBIOL 2015 69 445 61 10.1146/annurev-micro-091014-104115 26488281 11. Stoesser N Eyre DW Quan TP Godwin H Pill G Mbuvi E Epidemiology of Clostridium difficile in infants in oxfordshire, uk: risk factors for colonization and carriage, and genetic overlap with regional c. difficile infection strains PLoS ONE 2017 12 e0182307 10.1371/journal.pone.0182307 28813461 12. Plants-Paris K Bishoff D Oyaro MO Mwinyi B Chappell C Kituyi A Prevalence of Clostridium difficile infections among kenyan children with diarrhea INT J INFECT DIS 2019 81 66 72 10.1016/j.ijid.2019.01.024 30660798 13. Wang WP et al. Pediatrics: People’s Medical Press; 2018. 14. Callahan BJ McMurdie PJ Rosen MJ Han AW Johnson AJ Holmes SP Dada2: high-resolution sample inference from illumina amplicon data NAT METHODS 2016 13 581 3 10.1038/nmeth.3869 27214047 15. Koljalg U Nilsson RH Abarenkov K Tedersoo L Taylor AF Bahram M Towards a unified paradigm for sequence-based identification of fungi MOL ECOL 2013 22 5271 7 10.1111/mec.12481 24112409 16. Xiao L Wang J Zheng J Li X Zhao F Deterministic transition of enterotypes shapes the infant gut microbiome at an early age GENOME BIOL 2021 22 243 10.1186/s13059-021-02463-3 34429130 17. Chandrasekaran R Lacy DB The role of toxins in Clostridium difficile infection FEMS MICROBIOL REV 2017 41 723 50 10.1093/femsre/fux048 29048477 18. Pothoulakis C Lamont JT Microbes and microbial toxins: paradigms for microbial-mucosal interactions ii. The integrated response of the intestine to Clostridium difficile toxins AM J PHYSIOL-GASTR L 2001 280 G178 83 19. Holst E Helin I Mardh PA Recovery of Clostridium difficile from children Scand J Infect Dis 1981 13 41 5 10.1080/00365548.1981.11690365 7244558 20. Matsuki S Ozaki E Shozu M Inoue M Shimizu S Yamaguchi N Colonization by Clostridium difficile of neonates in a hospital, and infants and children in three day-care facilities of kanazawa, japan INT MICROBIOL 2005 8 43 8 15906260 21. Jangi S Lamont JT Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life J PEDIATR GASTR NUTR 2010 51 2 7 10.1097/MPG.0b013e3181d29767 22. Kociolek LK Espinosa RO Gerding DN Hauser AR Ozer EA Budz M Natural clostridioides difficile toxin immunization in colonized infants CLIN INFECT DIS 2020 70 2095 102 10.1093/cid/ciz582 31253983 23. Eglow R Pothoulakis C Itzkowitz S Israel EJ O’Keane CJ Gong D Diminished Clostridium difficile toxin a sensitivity in newborn rabbit ileum is associated with decreased toxin a receptor J CLIN INVEST 1992 90 822 9 10.1172/JCI115957 1325998 24. Kim J Smathers SA Prasad P Leckerman KH Coffin S Zaoutis T Epidemiological features of Clostridium difficileassociated disease among inpatients at children’s hospitals in the united states, 2001–2006 Pediatrics 2008 122 1266 70 10.1542/peds.2008-0469 19047244 25. Dong N Li ZR Qin P Qiang CX Yang J Niu YN Risk factors for Clostridioides difficile infection in children: a systematic review and meta-analysis J HOSP INFECT 2022 130 112 21 10.1016/j.jhin.2022.09.004 36108754 26. Slimings C Riley TV Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis J ANTIMICROB CHEMOTH 2014 69 881 91 10.1093/jac/dkt477 27. Khalil A Hendaus MA Elmagboul E Mohamed A Deshmukh A Elmasoudi A Incidence of Clostridium difficile infection and associated risk factors among hospitalized children in qatar THER CLIN RISK MANAG 2019 15 1343 50 10.2147/TCRM.S229540 31819461 28. Na JY Park JM Lee KS Kang JO Oh SH Kim YJ Clinical characteristics of symptomatic Clostridium difficile infection in children: conditions as infection risks and whether probiotics is effective PEDIATR GASTROENTERO 2014 17 232 8 29. Kuntz JL Chrischilles EA Pendergast JF Herwaldt LA Polgreen PM Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study BMC INFECT DIS 2011 11 194 10.1186/1471-2334-11-194 21762504 30. Cappella M Pugliese F Zucchini A Marchetti F Clostridium difficile enterocolitis and reactive arthritis: a case report and review of the literature CASE REP PEDIAT 2016 2016 1591753 31. Durand CL Miller PF Severe Clostridium difficile colitis and reactive arthritis in a ten-year-old child PEDIATR INFECT DIS J 2009 28 750 1 10.1097/INF.0b013e31819bdaa3 19633524 32. Liang Y He X Wang T Chen Y Huang H Tang W Massive hydrothorax and ascites as the primary manifestation of infection with Clostridium difficile: a case report and literature review FRONT PEDIATR 2020 8 254 10.3389/fped.2020.00254 32509714 33. Rojas GM Jarasvaraparn C Batten L Custodio H Gremse DA Clostridium difficile colitis complicating kawasaki disease in children: two case reports SAGE OPEN MED CASE R 2018 6 2050313X18781742 34. Price EH Wright VM Walker-Smith JA Tabaqchali S Clostridium difficile and acute enterocolitis ARCH DIS CHILD 1988 63 543 5 10.1136/adc.63.5.543 3389873 35. Loffler HA Pron B Mouy R Wulffraat NM Prieur AM Clostridium difficile-associated reactive arthritis in two children JOINT BONE SPINE 2004 71 60 2 10.1016/S1297-319X(03)00056-3 14769523 36. Nogueira H Costa CL Martins CS Morais M Quesada-Gomez C Carvalho C Infection with Clostridioides difficile ribotype 046 in a paediatric liver transplant patient Access Microbiol 2021 3 000268 10.1099/acmi.0.000268 34816088 37. Quesada-Gomez C Vargas P Lopez-Urena D Gamboa-Coronado MM Rodriguez-Cavallini E Community-acquired Clostridium difficile nap1/027-associated diarrhea in an eighteen month old child Anaerobe 2012 18 581 3 10.1016/j.anaerobe.2012.10.002 23116882 38. Yang Hong-bin Ying FANG Ren Xiao-xia, HAN Ya-nan. Clostridium difficile enteritis in children: a case report Chin J Practical Pediatr 2018 33 652 3 39. Guan Jun HE Lei-yan WANG Yu-huan WANG Chuan-qing HUANG Ying YU Hui Pseudomembranous enteritis caused by Clostridium difficile infection in a child: a case report Chin J Evid Based Pediatr | Chin J Evid Based Pediatr 2017 12 77 9 40. Kader A O’Hare B Valappil MK Non-antibiotic associated c. Difficile diarrhea in a 7 week-old infant INDIAN PEDIATR 2004 41 1045 8 15523132 41. Napolitano LM Edmiston CJ Clostridium difficile disease: diagnosis, pathogenesis, and treatment update SURGERY 2017 162 325 48 10.1016/j.surg.2017.01.018 28267992 42. Antonara S Leber AL Diagnosis of Clostridium difficile infections in children J CLIN MICROBIOL 2016 54 1425 33 10.1128/JCM.03014-15 26912759 43. Luna RA Boyanton BJ Mehta S Courtney EM Webb CR Revell PA Rapid stool-based diagnosis of Clostridium difficile infection by real-time pcr in a children’s hospital J CLIN MICROBIOL 2011 49 851 7 10.1128/JCM.01983-10 21209161 44. Polage CR Gyorke CE Kennedy MA Leslie JL Chin DL Wang S Overdiagnosis of Clostridium difficile infection in the molecular test era JAMA INTERN MED 2015 175 1792 801 10.1001/jamainternmed.2015.4114 26348734 45. Parnell JM Fazili I Bloch SC Lacy DB Garcia-Lopez VA Bernard R Two-step testing for Clostridioides difficile is inadequate in differentiating infection from colonization in children J PEDIATR GASTR NUTR 2021 72 378 83 10.1097/MPG.0000000000002944 46. Crobach MJ Planche T Eckert C Barbut F Terveer EM Dekkers OM European society of clinical microbiology and infectious diseases: update of the diagnostic guidance document for Clostridium difficile infection CLIN MICROBIOL INFEC 2016 22 Suppl 4 63 81 10.1016/j.cmi.2016.03.010 47. Shim JO Clostridium difficile in children: to treat or not to treat? PEDIATR GASTROENTERO 2014 17 80 4 48. Louie TJ Miller MA Mullane KM Weiss K Lentnek A Golan Y Fidaxomicin versus vancomycin for Clostridium difficile infection NEW ENGL J MED 2011 364 422 31 10.1056/NEJMoa0910812 21288078 49. Gough E Shaikh H Manges AR Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection CLIN INFECT DIS 2011 53 994 1002 10.1093/cid/cir632 22002980 50. McFarland LV Ship N Auclair J Millette M Primary prevention of Clostridium difficile infections with a specific probiotic combining lactobacillus acidophilus, l. Casei, and l. Rhamnosus strains: assessing the evidence J HOSP INFECT 2018 99 443 52 10.1016/j.jhin.2018.04.017 29702133 51. McFarland LV Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease AM J GASTROENTEROL 2006 101 812 22 10.1111/j.1572-0241.2006.00465.x 16635227 52. Hell M Bernhofer C Stalzer P Kern JM Claassen E Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic BENEF MICROBES 2013 4 39 51 10.3920/BM2012.0049 23434948 53. Semon AK Keenan O Zackular JP Clostridioides difficile and the microbiota early in life J PEDIAT INF DIS SOC 2021 10 3 S7 10.1093/jpids/piab063 54. Ahearn-Ford S, Berrington JE, Stewart CJ. Development of the gut microbiome in early life. EXP PHYSIOL; 2022. 55. Duan M Han Z Huang N Changes of intestinal microflora in neonatal necrotizing enterocolitis: a single-center study J INT MED RES 2020 48 300060520957804 10.1177/0300060520957804 32967507 56. Schonherr-Hellec S, Klein GL, Delannoy J, Ferraris L, Roze JC, Butel MJ et al. Clostridial strain-specific characteristics associated with necrotizing enterocolitis. APPL ENVIRON MICROB. 2018;84. 57. Roze JC Ancel PY Lepage P Martin-Marchand L Al NZ Delannoy J Nutritional strategies and gut microbiota composition as risk factors for necrotizing enterocolitis in very-preterm infants AM J CLIN NUTR 2017 106 821 30 10.3945/ajcn.117.152967 28659297 58. Reyman M van Houten MA van Baarle D Bosch A Man WH Chu M Impact of delivery mode-associated gut microbiota dynamics on health in the first year of life NAT COMMUN 2019 10 4997 10.1038/s41467-019-13014-7 31676793 59. Shao Y Forster SC Tsaliki E Vervier K Strang A Simpson N Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth Nature 2019 574 117 21 10.1038/s41586-019-1560-1 31534227 60. Backhed F Roswall J Peng Y Feng Q Jia H Kovatcheva-Datchary P Dynamics and stabilization of the human gut microbiome during the first year of life CELL HOST MICROBE 2015 17 690 703 10.1016/j.chom.2015.04.004 25974306 61. Mueller NT Differding MK Ostbye T Hoyo C Benjamin-Neelon SE Association of birth mode of delivery with infant faecal microbiota, potential pathobionts, and short chain fatty acids: a longitudinal study over the first year of life BJOG-INT J OBSTET GY 2021 128 1293 303 10.1111/1471-0528.16633 62. Lees EA Carrol ED Ellaby N Roberts P Corless CE Lenzi L Characterization of circulating Clostridium difficile strains, host response and intestinal microbiome in hospitalized children with diarrhea PEDIATR INFECT DIS J 2020 39 221 8 10.1097/INF.0000000000002559 31876614 63. Maziade PJ Ship N Sniffen JC Goldstein E Enhanced Clostridioides difficile infection prevention with a pharmacy-controlled policy that adds a 3-strain lactobacillus probiotic concomitantly to antibiotic therapy CLIN INFECT DIS 2021 73 1524 7 10.1093/cid/ciab414 33966076 64. Malmqvist L Ullberg M Hed MI Nilsson A Clostridium difficile infection in children: epidemiology and trend in a swedish tertiary care hospital PEDIATR INFECT DIS J 2019 38 1208 13 10.1097/INF.0000000000002480 31738336 65. Laursen MF. Gut microbiota development: influence of diet from infancy to toddlerhood. ANN NUTR METAB. 20211–14.